As potential next-generation therapeutics and research tools, few life sciences technologies hold more promise than genome-editing proteins — molecules that can be programmed to alter specific genes in order to treat or even cure genetic diseases.
There’s at least one catch though — getting genome-editing proteins into cells, where they need to be to access the genome, is a major challenge, especially in live animals or human patients.
Conventionally, researchers have delivered the DNA encoding these genome-editing proteins into cells and then relied on the cells to produce the corresponding genome-editing proteins. But many DNA delivery strategies cannot be used in animals or human patients. Other DNA delivery strategies such as infecting with viruses that inject DNA into cells can raise complicating long-term safety issues, especially when the editing the human genome is involved.
What may be more promising, the new study finds, is the direct delivery of genome-editing proteins into cells, rather than delivery of the corresponding genes that encode these proteins. And a class of molecules that can open the door for genome-editing proteins, as it turns out, is probably already on the shelves of many biologists.
Led by Professor of Chemistry and Chemical Biology David Liu and his group members Drs. John Zuris and David Thompson, a team of Harvard researchers have developed a system that uses commercially-available molecules called cationic lipids — essentially long, greasy molecules that carry a positive charge at one end — to efficiently introduce genome-editing proteins into cells, and have even demonstrated that the technology can be used to modify genes in living animals. The study is described in an October 30 paper in Nature Biotechnology.
“Current drugs that treat genetic diseases cannot address the root cause of the disease,” Liu explained. “Unlike infectious diseases, for example, which we treat by killing the disease-causing agent, in the case of diseases that come from mutations in our own genes, one has to go into the cells and do surgery on our genomes to fix the root cause. Thanks to recent discoveries by scientists around the world, we now have genome-editing proteins that can do the surgery. But the challenge is that these proteins, like virtually all proteins, do not enter cells spontaneously.
“In this study we describe a method to very potently deliver genome-editing proteins into cells,” Liu added. “And we observed efficient genome modification using this method not just in cultured cells, but also in living animals.”
Though he warned that no system, including this one, will be a one-size-fits-all delivery solution, Liu believes that delivering genome-editing proteins into cells could offer hope to patients suffering from a host of conditions, including certain diseases of the eye, ear, liver, muscles, and blood.
One condition that’s already in researchers’ crosshairs is deafness.
Working with Zheng-Yi Chen, an Associate Professor of Otology and Laryngology at Harvard Medical School and researcher at Massachusetts Eye and Ear Infirmary, Liu and colleagues used the newly-developed system to modify genes in specialized “hair cells” in the inner ear of mice. Hair cell damage, either from environmental or genetic factors, is a common cause of hearing loss.
A common strategy for introducing proteins into cells, Liu said, has been to rely on positively charged proteins. Because the exterior of mammalian cells are decorated with negatively charged molecules, positively charged proteins are stick to them, causing them to be engulfed by cells in compartments called endosomes. Liu and his students previously developed one such strategy that uses positively “supercharged” proteins as delivery vehicles.
“The key difficulty, which has been known for decades, is that getting cargo out of endosomes is very difficult,” Liu said. “The efficiency with which a protein will spontaneously escape an endosome is very low — maybe as low as one-in-a-million under normal circumstances.”
To develop a system that would allow for the more efficient delivery of proteins into cells, Liu and colleagues took the opposite approach, one that involved mimicking the way scientists deliver nucleic acids like DNA and RNA into cells.
That system relies on positively charged molecules called cationic lipids, which bind with negatively charged nucleic acids to form structures called liposomes. Once formed, there are at least two ways for liposomes to deliver their contents into a cell. In some cases, Liu explained, the liposome may fuse with the cell’s membrane, releasing its cargo. Alternately, the liposome may be taken in as an endosome, and then release its contents if the liposome and endosome membranes fuse.
“We had the very simple idea to use the same commercially-available cationic lipids researchers use to deliver DNA and RNA to deliver proteins. But instead of using super-positively charged proteins, we use super-negatively charged proteins, which resemble nucleic acids in their highly negatively charged state.” Liu said. “The potency of delivering proteins that are associated with highly negatively charged molecules using cationic lipids is approximately 1,000 times greater than delivering proteins using positively charged proteins or peptides.”
Importantly, the team’s experiments showed that the new system, when applied to the delivery of genome editing proteins, results in target gene modification that is at least as efficient as the best results they observed from the delivery of DNA encoding genome-editing proteins. But Liu and coworkers showed that the specificity of genome editing — how accurately the targeted genes are modified versus modification of other sites in the human genome — was much higher from protein delivery instead of DNA delivery.
This outcome was what the researchers hoped to see. “Following DNA delivery, the encoded proteins can be expressed in difficult-to-regulate amounts for long periods of time,” Liu said. “There has always been a mismatch between DNA delivery and the desired outcome of genome editing. In genome editing, the mission is to fix one or two copies of a gene. After a genome-editing protein finishes that mission, you want it to go away, because the only things it can do after that point are undesired and possibly harmful.
“So protein delivery, which is transient and short-lived, seemed to be a better match than DNA delivery for most genome-editing applications.”
Ultimately, Liu believes genome-editing proteins may serve as the next generation of therapies for a host of disorders that have been difficult to treat.
“We hope this approach to protein delivery will help connect where genome editing is now to where the field needs to be in order to realize the therapeutic potential of these proteins to address genetic diseases,” Liu said.